Nicole E. Scangarella-Oman

Author

Also Known As

N Scangarella-Oman, N. E. Scangarella-Oman, Nicole E Scangarella-Oman, Nicole E. Scangarella-Oman, Nicole Scangarella-Oman, Scangarella-Oman, Nicole E.

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)JMI Laboratories GlaxoSmithKline (United Kingdom)Becton Dickinson (United States)Age UK

About

Nicole E. Scangarella-Oman is an author at GlaxoSmithKline (United States) specializing in medicine, drug resistance, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	232
2	Pharmacology	5	5	166
3	Microbiology	4	4	153
4	Health Sciences	3	3	142
5	Antibiotics	3	3	177

Nicole E. Scangarella-Oman

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation Stephanie N. Taylor, David H. Morris, Ann Avery, Clinical Infectious Diseases	2018	158
Antimicrobial Resistance Trends in Urine <i>Escherichia coli</i> Isolates From Adult and Adolescent Females in the United States From 2011 to 2019: Rising ESBL Strains and Impact on Patient Management Keith S. Kaye, Vikas Gupta, Aruni Mulgirigama, Clinical Infectious Diseases	2021	124
<i>In Vitro</i> Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens Douglas J. Biedenbach, S. Bouchillon, Meredith Hackel, Antimicrobial Agents and Chemotherapy	2016	121
Bacterial Resistance to Leucyl-tRNA Synthetase Inhibitor GSK2251052 Develops during Treatment of Complicated Urinary Tract Infections Karen O’Dwyer, Aaron Spivak, Karen Ingraham, Antimicrobial Agents and Chemotherapy Microbial PathogensEscherichia Coli IsolatesAntibiotic ResistanceBacterial PathogensDrug Resistance	2014	97
Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae Nicole E. Scangarella-Oman, Mohammad Sharif Hossain, Paula Dixon, Antimicrobial Agents and Chemotherapy	2018	92
Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections William O’Riordan, Courtney Tiffany, Nicole E. Scangarella-Oman, Antimicrobial Agents and Chemotherapy	2017	77
Gepotidacin (GSK2140944) <i>In Vitro</i> Activity against Gram-Positive and Gram-Negative Bacteria Robert K. Flamm, David J. Farrell, Paul R. Rhomberg, Antimicrobial Agents and Chemotherapy	2017	73
In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae Susanne Jacobsson, Daniel Golparian, Nicole E. Scangarella-Oman, Journal of Antimicrobial Chemotherapy	2018	72
<i>In Vitro</i> Activity of Gepotidacin (GSK2140944) against Neisseria gonorrhoeae D. J. Farrell, Hélio S. Sader, Paul R. Rhomberg, Antimicrobial Agents and Chemotherapy	2017	68
Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials Florian Wagenlehner, Caroline Perry, Thomas M. Hooton, The Lancet UrologyAntimicrobial StewardshipAntibioticsPharmacotherapyAntimicrobial Chemotherapy	2024	66

Page 1